Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06019936
Other study ID # MT2004-II-C01
Secondary ID CTR20232066
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 10, 2023
Est. completion date October 10, 2025

Study information

Verified date August 2023
Source Shaanxi Micot Technology Limited Company
Contact LanLan Song, Master
Phone +8615929300901
Email songlanlan@micot.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The main questions it aims to answer are: 1. The Efficacy of MT2004 Capsule in Cholestatic and Mixed DILI subjects 2. The Safety and Pharmacokinetic characteristic of MT2004 Capsule in Cholestatic and Mixed DILI subjects 3. The mechanism of using MT2004 Capsule on Cholestatic and Mixed DILI subjects


Description:

Xi'An Aolitai Pharmaceutical Technology Co Ltd is developing MT2004, a novel investigational synthetic small molecule farnesoid X receptor (FXR) agonist targeted to the liver. The MT2004 was designed as the prodrug and the metabolites MT2004-met1 of MT2004 will act to the FXR receptor to regulate a series of genes expression. It also plays an important role in the metabolism of bile acids, lipids and sugars. The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The whole study will be divied to three stages including screening period (14 Days before the treatment), treatment period (the participants will be randomized to receive MT2004, or placebo orally (BID), for 12 weeks) and follow-up period. The study aims to recruit total of 80 subjects with Cholestatic and Mixed DILI, in which 12 of subjects will be firstly enrolled and allocated to the MT2004 group (Dose level: 25mg) as well as control group with the proportion of 2:1 by using the stratified randomization method. During the whole study, the adjustment of the subjects amount, the dose level as well as randomization proportion will based on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID. The placebo will be used in this study, and the researchers will compare the placebo and test article to see the safety and efficacy.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date October 10, 2025
Est. primary completion date August 10, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 1. 18= age = 75 years, male or female. 2. When diagnosis of acute DILI, the liver biochemical threshold of patients must meet one of the following criteria: :(1) ALT =5 ×ULN;(2) ALP =2× ULN;(3) ALT=3× ULN and TBil =2×ULN. 3. ALP =2× ULN, and conform to the clinical classification of cholestatic type or mixed type DILI in the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition) (cholestatic type: R value =2; Mixed type: 2<R value <5). 4. Excluded other common causes of acute liver injury, such as acute viral hepatitis A, B, C, E, autoimmune hepatitis, biliary tract disease, PBC, etc. (Exclusive diagnostic tests completed in our hospital or other hospitals after this suspected acute DILI event or within 2 months before screening were acceptable) 5. RUCAM causality scale score =6 points; If the RUCAM score is between the 3-5 it is necessary to evaluate the causal relationship by three experts according to the evaluation criteria of expert opinions in the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition), and at least two experts determine that the liver injury of the patients are "likely", "very likely" or "definitely" caused by drugs. 6. The serious level of DILI is within level 1-2 based on the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition). 7. The duration of this liver injury is less than 6 months. 8. The female with fertility must have had a negative pregnancy test results before being enrolled, or at least 1 year after pausimenia, or permanent sterilization =6 weeks(There should have a recording of hysterectomy, bilateral salpingo-oophorectomy). The female and their male partners with the fertility potential agree to utilize the effective contraceptive methods(the following two methods can be selected: 1. any of the condom, diaphragm, Sponge or Cervical Cap with with Spermicide ). 9. Fully understand the study process of the clinical trial, and provide the signed ICF of joinning the clinical trial. Exclusion Criteria: - 1. Acute or chronic liver failure or liver decompensation 2. The history of liver decompensation or portal hypertension history 3. Moderate or above renal insufficiency, creatinine clearance (Ccr) < 60mL/min (according to the MDRD formula). 4. Patients with serious diabetes and had poor control of blood sugar (HbA1c>10%) 5. Serious sysmetic diseases of cardiovascular, respiratory, neurological, urinary, digestive, and for any reason which, in the opinion of the Investigator think the subject is not suitable for participating in the study. 6. The predict survival period < 6 months. 7. Utilization of Perursodeoxycholic acid within 14 days before the treatment. 8. Utilization of S-adenosylmethionine within 1 days before the treatment. 9. The patients must regularly utilize the known strong CYP3A4/3A5 inhibitors such as Clarithromycin, Itraconazole, ketoconazole, Ritonavir, rifampicin, phenytoin, carbamazepine within 1 week before the treatment or for the whole study period. 10. Allergies or intolerances to study drug ingredients 11. Patients are under the gestation, lactation, or patients have the pregnancy planning during the study period and 90 days after the end of the clinical trial 12. Patients are not willing to ban the alcohol during the study period. 13. Patients had joined the other clinical trials within 3 months before the administration. 14. Other conditions that the investigator think the subject is not suitable for participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MT2004 Capsule
The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
MT2004 Capsule Placebo
The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.

Locations

Country Name City State
China Shanghai Jiaotong University School of Medicine,Renji Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Xi'An Aolitai Pharmaceutical Technology Co Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety endpoint Adverse Events(AEs) will be recorded and evaluated for their seriousness, severity, and relationship to the study drug. From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 12 weeks.
Primary Primary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on serum ALP compared to baseline. On the week 4 after the administration
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on ALP compared to baseline. On the week 2,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the percentage of patients whose ALP decreased by more than 15% from baseline. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the recovery rate of ALP. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on GGT compared to baseline. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the recovery rate of GGT. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on ALT compared to baseline. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the recovery rate of ALT. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on AST compared to baseline. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the recovery rate of AST. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on TBIL compared to baseline. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the decreasing rate on TBA compared to baseline. On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the area of serum ALP decreasing rate-time curve. On the week 2,4,8,12 after the administration
Secondary Secondary efficacy endpoint The efficacy of MT2004 will be evaluated based on the percentage of patients developed to DILI level 3-4 after the administration. On the week 2,4,8,12 after the administration and the week 4 follow-up period
See also
  Status Clinical Trial Phase
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05060289 - A Prognostic Model for Drug-induced Liver Injury in China
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Completed NCT03211208 - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
Not yet recruiting NCT02061826 - Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA) N/A
Completed NCT02182167 - A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Phase 2/Phase 3
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Not yet recruiting NCT03091608 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule N/A
Not yet recruiting NCT03091556 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill. N/A
Not yet recruiting NCT03091244 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule. N/A
Not yet recruiting NCT03060252 - Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill N/A
Not yet recruiting NCT03091218 - Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule. N/A
Completed NCT02407964 - A Retrospective Study on Drug Induced Liver Injury in China N/A
Active, not recruiting NCT05144217 - Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo Phase 2/Phase 3
Completed NCT01705041 - Preliminary Evaluation of a Point-Of-Care Liver Function Test N/A
Recruiting NCT02086708 - Ultrasound Method to Measure Fibrosis of the Liver in Children N/A
Recruiting NCT05465642 - Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Completed NCT01434173 - Risk of Acute Liver Injury in Users of Antimicrobials N/A
Completed NCT05532345 - Discrimination of DILI and AIH by Artificial Intelligence
Completed NCT03602703 - Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs